BioNano Genomics, Inc. (NASDAQ: BNGO) reported Q4 EPS of $. Revenue for the quarter came in at $4 million versus the consensus estimate of $3.34 million.

“We are very pleased with how Saphyr is becoming an essential tool for genome analysis and digital cytogenetics worldwide,” said Erik Holmlin, Ph.D., CEO of Bionano. “We are seeing accelerated interest in our Saphyr system, as our differentiated capabilities, the unique detection of structural variations, and our new price point below $500 per whole human genome sample continues to drive demand.”

Dr. Holmlin added, “We continue to focus on expanding and executing on our commercial plan. We plan to continue building our commercial team, and look forward to executing on our strategies to make structural variation analysis as commonplace as next-generation sequencing and to lead the emergence of digital cytogenetics.”

For earnings history and earnings-related data on BioNano Genomics, Inc. (BNGO) click here.